Monday, September 24, 2018

New way to target advanced breast cancers

IL1b, a member of the interleukin 1 family of cytokines (proteins released by certain cells of the immune system) drives the inflammation often found in cancer, and appears as an 'IL1 signature' in women with HER2-negative metastatic breast cancer. This signature can not only serve as a diagnostic tool for HER2-negative cancers but also offer an effective treatment target.

https://www.sciencedaily.com/releases/2018/09/180920104421.htm

No comments:

Post a Comment